YWYing Wang

Ying Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ying Wang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Denghai Zhang

    Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital, China

    3 shared publications
  • Fanfan Cao

    School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, PR China

    3 shared publications
  • Bin Peng

    School of Medicine, Shanghai University, Shanghai 200444, China; Shanghai Health Commission Key Lab of Artificial Intelligence-Based Management of Inflammation and Chronic Diseases, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, China

    2 shared publications
  • Bingcang Huang

    Department of Radiology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, 200135, China

    2 shared publications
  • Chunxin Yang

    Pharmaceutical Department, Zhong Shan Hospital, Shanghai Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, China.

    2 shared publications
  • Georges Uzan

    INSERM UMR-S 1193, Université Paris-Saclay, 94800 Villejuif, France

    2 shared publications

Latest Publications

  • Ischemic stroke nanomedicine

    by Lan Luo, Meiqi Chang, Ying Wang, Yu Chen, Bingcang Huang


  • Celastrol Ameliorated Alzheimer’s Disease in Mice by Enhancing TBX21/TREM2 Expression in Microglia and Inhibiting Tau Phosphorylation

    by Fanfan Cao, Pan Zhang, Yongbin Chi, Ying Wang, Limin Xu, Denghai Zhang

    Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder that is typified by the formation of senile plaques containing Aβ and neurofibrillary tangles containing tau in a hyperphosphorylated state. Celastrol, a natural compound, has proven effective in alleviating AD pathology by enhancing autophagy and reducing tau aggregates. The present study investigates the neuroprotective mechanisms of celastrol, with a particular focus on the participation of the transcription factor T-box transcription factor 21 (TBX21) and triggering receptor expressed on myeloid cells 2 (TREM2) in microglial cells. In AD mouse models, celastrol upregulated TBX21 and TREM2, suppressed phosphorylated tau and inflammatory cytokines, and restored neuronal viability. In vitro, celastrol-treated microglia enhanced neuronal survival under amyloid-beta (Aβ) stress, effects abolished by TBX21/TREM2 knockdown. Mechanistically, TBX21 directly bound the TREM2 promoter to regulate its expression. These findings identified the TBX21-TREM2 axis as a therapeutic target for AD.


  • Open Access

    Celastrol attenuates Alzheimer's disease-mediated learning and memory impairment by inhibiting endoplasmic reticulum stress-induced inflammation and oxidative stress

    by Fanfan Cao, Limin Xu, Xiaoxue He, Yongbin Chi, Ying Wang, Denghai Zhang, Qiuyun Liu

    Introduction: Alzheimer's disease (AD) is triggered by biological mechanisms such as neuroinflammation and oxidative stress. Endoplasmic reticulum (ER) stress can lead to the expression of molecular chaperones in the ER, which helps in restoring cellular homeostasis. Researchers have highlighted the role of ER stress in the progression of AD, suggesting that regulating it could be a potential treatment strategy for AD.Material and methods: We induced AD in mice by injecting amyloid beta-peptide 25-35 (Aβ25-35) bilaterally into the CA1 of the dorsal hippocampus. Some mice were administered celastrol intraperitoneally before the Aβ25-35 injection, while others received it after the injection. The mice underwent the Barnes maze cognitive test and Morris water maze test to assess learning and memory impairment. Levels of interleukin (IL)-1β, tumor necrosis factor alpha, and IL-10 were measured to evaluate inflammation, while total antioxidant capacity, catalase, Malondialdehyde, and superoxide dismutase levels were analyzed to estimate oxidative stress.Results: Our study showed that pre-treatment with celastrol could prevent learning and memory decline in AD mice by reducing inflammation and oxidative stress. Celastrol also inhibited AD-induced inflammation and oxidative stress. Additionally, celastrol suppressed AD progression by targeting ER stress. These results suggest that celastrol treatment could be beneficial in addressing learning and memory deficits in AD, paving the way for potential neuroprotective treatments.Conclusions: Celastrol effectively improved learning and memory impairments in AD mice by targeting ER stress-induced inflammation and oxidative stress. This highlights the potential of celastrol as a therapeutic agent for AD.


  • Open Access

    Dynamic contrast-enhanced MR imaging in identifying active anal fistula after surgery

    by Weiping Lu, Xiaoyan Li, Wenwen Liang, Kai Chen, Xinyue Cao, Xiaowen Zhou, Ying Wang, Bingcang Huang

    Background: It is challenging to identify residual or recurrent fistulas from the surgical region, while MR imaging is feasible. The aim was to use dynamic contrast-enhanced MR imaging (DCE-MRI) technology to distinguish between active anal fistula and postoperative healing (granulation) tissue. Methods: Thirty-six patients following idiopathic anal fistula underwent DCE-MRI. Subjects were divided into Group I (active fistula) and Group IV (postoperative healing tissue), with the latter divided into Group II (≤ 75 days) and Group III (> 75 days) according to the 75-day interval from surgery to postoperative MRI reexamination. MRI classification and quantitative analysis were performed. Correlation between postoperative time intervals and parameters was analyzed. The difference of parameters between the four groups was analyzed, and diagnostic efficiency was tested by receiver operating characteristic curve. Results: Wash-in rate (WI) and peak enhancement intensity (PEI) were significantly higher in Group I than in Group II (p = 0.003, p = 0.040), while wash-out rate (WO), time to peak (TTP), and normalized signal intensity (NSI) were opposite (p = 0.031, p = 0.007, p = 0.010). Area under curves for discriminating active fistula from healing tissue within 75 days were 0.810 in WI, 0.708 in PEI, 0.719 in WO, 0.783 in TTP, 0.779 in NSI. All MRI parameters were significantly different between Group I and Group IV, but not between Group II and Group III, and not related to time intervals. Conclusion: In early postoperative period, DCE-MRI can be used to identify active anal fistula in the surgical area. Trial registration: Chinese Clinical Trial Registry: ChiCTR2000033072.


  • Open Access

    CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma

    by Lianyong Liu, Mingjun Gu, Junhua Ma, Ying Wang, Miao Li, Hui Wang, Xin Yin, Xiangqi Li

    Background: Emerging evidence indicates that circular RNAs (circRNAs) and m6A RNA methylation participate in the pathogenesis and metastasis of multiple malignancies including hepatocellular carcinoma (HCC). However, it remains undocumented how circRNAs form a feedback loop with the m6A modification contributing to HCC. Methods: A novel hsa_circ_0017114 (circGPR137B) was identified from three pairs of primary HCC and adjacent normal tissues by circRNA expression profiling. The association of circGPR137B and miR-4739 with clinicopathological parameters and prognosis in patients with HCC was analyzed by RT-qPCR, fluorescence in situ hybridization and TCGA cohorts. The role of circGPR137B in HCC was estimated in vitro and in vivo. RT-qPCR, western blot, m6A dot blot, RIP, MeRIP and dual-luciferase reporter assays were used to validate the reciprocal regulation of the feedback loop among circGPR137B, miR-4739 and m6A demethylase FTO. Meanwhile, the expression, function and prognosis of FTO in HCC were investigated by RT-qPCR, western blot, TCGA and rescue experiments. Results: We identified a new dramatically downregulated circGPR137B in HCC tissues, and found that downregulation of circGPR137B or upregulation of miR-4739 was associated with poor prognosis in patients with HCC. Ectopic expression of circGPR137B strikingly repressed the proliferation, colony formation and invasion, whereas knockdown of circGPR137B harbored the opposite effects. Moreover, restored expression of circGPR137B inhibited tumor growth and lung metastasis in vivo. Further investigations showed that circGPR137B, co-localized with miR-4739 in the cytoplasm, acted as a sponge for miR-4739 to upregulate its target FTO, which mediated m6A demethylation of circGPR137B and promoted its expression. Thus, a feedback loop comprising circGPR137B/miR-4739/FTO axis was formed. FTO suppressed cell growth and indicated favorable survival in patients with HCC. Conclusion: Our results demonstrate that circGPR137B inhibits HCC tumorigenesis and metastasis through the circGPR137B/miR-4739/FTO feedback loop. This positive feedback mechanism executed by functional coupling between a circRNA sponge and an m6A modification event suggests a model for epigenetics.


  • Circular RNA circPIP5K1A promotes non‐small cell lung cancer proliferation and metastasis through miR‐600/HIF‐1α regulation

    by Yongbing Chi, Qiancheng Luo, Yuting Song, Fangsong Yang, Ying Wang, Mingming Jin, Denghai Zhang

    Circular RNAs (circRNAs) have an important function in human diseases, especially in cancer. circRNA hsa_circ_0014130 (circPIP5K1A), a particularly abundant circRNA, participates in the tumorigenesis of non‐small cell lung cancer (NSCLC), although the underlying regulatory mechanism remains unclear. Here, we investigated the circPIP5K1A role in NSCLC. Expression of circPIP5K1A in NSCLC cell lines was explored with quantitative real‐time PCR. The effect of circPIP5K1A on NSCLC was evaluated with circPIP5K1A silencing, miR‐600 mimic transfection, and hypoxia‐inducible factor (HIF)‐1α overexpression, followed by assessment of cell proliferation, metastasis, and tumorigenesis in nude mice. The subcellular localization of circPIP5K1A was evaluated via fluorescence in situ hybridization (FISH), and correlation between circPIP5K1A, miR‐600, and HIF‐1α was assessed by luciferase assay. The data demonstrated that circPIP5K1A expression was increased in NSCLC cells. FISH showed that circPIP5K1A localized to the cytoplasm. The circPIP5K1A knockdown suppressed NSCLC cell metastasis and proliferation by promoting expression of miR‐600. Overexpression of miR‐600 inhibited HIF‐1α‐mediated metastasis and proliferation of NSCLC cell by downregulating the endothelial mesenchymal transition‐related proteins, Snail and vimentin, and upregulating E‐cadherin. In vivo experiments illustrated that circPIP5K1A silence suppressed tumor growth and pulmonary metastasis. The circPIP5K1A may function as an miR‐600 sponge to facilitate NSCLC proliferation and metastasis by promoting HIF‐1α. A bifluorescein reporter experiment confirmed that miR‐600 was the circPIP5K1A target, and miR‐600 interacted with the 3′ untranslated region of HIF‐1α. These results show that circPIP5K1A acted as a tumor promoter through a novel circPIP5K1A/miR‐600/HIF‐1α axis, which provides candidate markers and therapeutic targets for NSCLC.


  • Open Access

    Inhibiting inducible miR-223 further reduces viable cells in human cancer cell lines MCF-7 and PC3 treated by celastrol

    by Lu Cao, Xue Zhang, Fanfan Cao, Ying Wang, Yufan Shen, Chunxin Yang, Georges Uzan, Bin Peng, Denghai Zhang

    Celastrol is a novel anti-tumor agent. Ways to further enhance this effect of celastrol has attracted much research attention. Here, we report that celastrol treatment can elevate miR-223 in human breast cancer cell line MCF-7 and prostate cancer PC3. Down-regulating miR-223 could increase the number of viable cells, yet it further reduced viable cells in samples that were treated by celastrol; up-regulation of miR-223 displayed opposite effects. Celastrol’s miR-223 induction might be due to NF-κB inhibition and transient mTOR activation: these two events occurred prior to miR-223 elevation in celastrol-treated cells. NF-κB inhibitor, like celastrol, could induce miR-223; the induction of miR-223 by NF-κB inhibitor or celastrol was reduced by the use of mTOR inhibitor. Finally and interestingly, miR-223 also could affect NF-κB and mTOR and the effects were different between cells treated or not treated with celastrol, thus providing an explanation for differing effects of miR-223 alteration on cellular viability in the presence of celastrol or not. For the first time, we disclose that celastrol could induce miR-223 in breast and prostate cancer cells, and that inhibiting miR-223 could further reduce the living cells in celastrol-treated cancer cell lines. We thus provide a novel way to increase celastrol’s anti-cancer effects.


  • Open Access

    Peptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells

    by Bin Peng, Xue Zhang, Fanfan Cao, Ying Wang, Limin Xu, Lu Cao, Chunxin Yang, Maoquan Li, Georges Uzan, Denghai Zhang

    Celastrol is a promising anti-tumor agent, yet it also elevates heat shock proteins (HSPs), especially HSP70, this effect believed to reduce its anti-tumor effects. Concurrent use of siRNA to increase celastrol’s anti-tumor effects through HSP70 interference has been reported, but because siRNA technology is difficult to clinically apply, an alternative way to curb unwanted HSP70 elevation caused by celastrol treatment is worth exploring.